Immunovant discontinues batoclimab after failed trials, pivots fully to IMVT-1402

Filed May 20, 2026 · Period ending March 31, 2026 · Compared to 10-K May 29, 2025 · ~1 min read

Key Changes

• high

  Batoclimab discontinued across all indications after two Phase 3 TED trials missed primary endpoints in April 2026; company now focuses exclusively on IMVT-1402 with six active trials.

  Business: batoclimab discontinuation verify on EDGAR →
• high

  $42.5M in non-cancelable contractual costs accrued from batoclimab discontinuation, with $39.0M hitting fiscal 2026 R&D expenses as one-time charge.

  MD&A: batoclimab contractual costs verify on EDGAR →
• high

  Raised $543.7M in December 2025 equity offering; cash runway now extends through potential GD commercial launch (previously only through 2027 data readout).

  MD&A: December 2025 equity raise verify on EDGAR →